Evidence map›Paper›PMID 36252158›Full record

ArticleJCO global oncology2022

Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap.

Parsa Erfani, Michael Bates, Pat Garcia-Gonzalez, Dan A Milner, Timothy R Rebbeck, Deogratias Ruhangaza, Lawrence N Shulman, Temidayo Fadelu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parsa ErfaniHarvard Medical School, Boston, MA.ORCID 0000-0002-5738-0556
Michael BatesMedical and Scientific Affairs, Oncology, Cepheid, Sunnyvale, CA.
Pat Garcia-GonzalezThe Max Foundation, Global Headquarters, Seattle, WA.ORCID 0000-0002-4544-9253
Dan A MilnerAmerican Society for Clinical Pathology, Chicago, IL.ORCID 0000-0002-6685-8208
Timothy R RebbeckHarvard TH Chan School of Public Health, Boston, MA.ORCID 0000-0002-4799-1900
Deogratias RuhangazaDepartment of Pathology, Butaro Cancer Center of Excellence, Burera, Rwanda.
Lawrence N ShulmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8661-473X
Temidayo FadeluHarvard Medical School, Boston, MA.ORCID 0000-0002-1323-4119

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
FIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsPathology, MolecularHumansTechnology

Identifiers

PMID36252158
PMCPMC9812500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.